FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval

BY news

If approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind currently on the U.S. market after Leqembi from Biogen and Eisai.
source
Sponsor:News technical sponsor
Sponsor:News AI sponsor
Sponsor: AI sponsor
Sponsor: AI sponsor

Leave a Comment

Vélemény, hozzászólás?

Az e-mail címet nem tesszük közzé. A kötelező mezőket * karakterrel jelöltük

Related Posts

BusinessITPopularTrends

Better Siri is coming: what Apple’s research says about its AI plans

By David Pierce, editor-at-large and Vergecast co-host with over a decade of experience covering consumer tech. Previously, at Protocol, The Wall Street Journal, and Wired.It would be easy to think th

BusinessITNewsPopularTrends

Tesla Semi fire in California took 50,000 gallons of water to extinguish

The National Transportation Safety Board said on Friday that a Tesla Semi crash last month closed down an artery of Interstate 80 for 15 hours.sourceSponsor:News technical sponsor Sponsor:News AI spon

BusinessITNewsPopularTrends

Russia warns France over Telegram founder's detainment, suggests it may be politically motivated

The detainment of Telegram founder Pavel Durov could be considered political if France fails to provide serious evidence of his guilt, the Kremlin said Tuesday.sourceSponsor:News technical sponsor Spo

Copyright © 2024 | WordPress Theme: Xews Lite